| Sissel M Kjelstrup, MD | |
|
2222 Nw Lovejoy St, Suite 422, Portland, OR 97210-3033 | |
| (503) 227-7117 | |
| Not Available |
| Full Name | Sissel M Kjelstrup |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Location | 2222 Nw Lovejoy St, Portland, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881759132 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | MD16851 (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sissel M Kjelstrup, MD 2222 Nw Lovejoy St, Suite 422, Portland, OR 97210-3033 Ph: (503) 227-7117 | Sissel M Kjelstrup, MD 2222 Nw Lovejoy St, Suite 422, Portland, OR 97210-3033 Ph: (503) 227-7117 |
News Archive
Patients with chronic obstructive pulmonary disease (COPD) who also have allergic disease have higher levels of respiratory symptoms and are at higher risk for COPD exacerbations, according to a new study from researchers at Johns Hopkins University in Baltimore.
A study from USC researchers provides new understanding of the relationship between "sexting" and sexual behavior in early adolescence, contributing to an ongoing national conversation about whether sexually explicit text messaging is a risk behavior or just a technologically-enabled extension of normal teenage flirtation. The latest research, published in the July 2014 issue of the journal Pediatrics, found that among middle school students, those who reported receiving a sext were 6 times more likely to also report being sexually active.
Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.
A recently approved angina drug may also represent a powerful new treatment for a rare hereditary syndrome that places teens at risk for sudden cardiac death, according to research presented on April 1st at the 57th Annual Scientific Sessions of the American College of Cardiology (ACC) in Chicago.
› Verified 6 days ago
Dr. Alison Marie Small, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 3303 Sw Bond Ave, Portland, OR 97239 Phone: 503-418-3376 | |
Milie Fang, DO Dermatology Medicare: Not Enrolled in Medicare Practice Location: 3303 S Bond Ave Dept, Portland, OR 97239 Phone: 503-494-1375 | |
Bert G Tavelli, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2525 Nw Lovejoy St Ste 400, Portland, OR 97210 Phone: 503-223-1933 Fax: 503-223-1947 | |
Natasha Fewkes Carter, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4914 Sw 1st Ave, Portland, OR 97239 Phone: 310-701-8274 | |
Dr. Samuel Fritz Bremmer, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-494-8211 | |
Oluwadamilare Olalekan Ajayi, MD Dermatology Medicare: Medicare Enrolled Practice Location: 3303 S Bond Ave, Portland, OR 97239 Phone: 503-418-3376 Fax: 503-494-6968 | |
Diane Romayne Baker, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 9495 Sw Locust St Ste A&e, Portland, OR 97223 Phone: 503-471-0500 Fax: 503-471-0504 |